Cargando…

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces cardiovascular events in type 2 diabetes (T2DM) and is associated with a reduction in left ventricular (LV) mass index. However, the impact on right ventricular (RV) remodeling is unknown. Accordingly, the objective of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarak, Bradley, Verma, Subodh, David Mazer, C., Teoh, Hwee, Quan, Adrian, Gilbert, Richard E., Goodman, Shaun G., Bami, Karan, Coelho-Filho, Otávio R., Ahooja, Vineeta, Deva, Djeven P., Garg, Vinay, Gandhi, Sumeet, Connelly, Kim A., Yan, Andrew T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491405/ https://www.ncbi.nlm.nih.gov/pubmed/34607574 http://dx.doi.org/10.1186/s12933-021-01390-8

Ejemplares similares

Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
por: Puar, Pankaj, et al.
Publicado: (2023)

Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
por: Garg, Vinay, et al.
Publicado: (2020)

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
por: Barbour, William, et al.
Publicado: (2023)

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
por: Lam, Carolyn S. P., et al.
Publicado: (2019)

IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
por: Puar, Pankaj, et al.
Publicado: (2023)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Stage‐based approach to predict left ventricular reverse remodeling after mitral repair
por: Hibino, Makoto, et al.
Publicado: (2022)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Endothelial cell control of thrombosis
por: Yau, Jonathan W., et al.
Publicado: (2015)

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
por: Sposito, Andrei C., et al.
Publicado: (2022)

Atrial structure and function in middle‐aged, physically‐active males and females: A cardiac magnetic resonance study
por: Glibbery, Meghan, et al.
Publicado: (2021)

Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitation
por: Rumman, Rawan K, et al.
Publicado: (2023)

Treatment Inertia in Patients With Familial Hypercholesterolemia
por: Langer, Anatoly, et al.
Publicado: (2021)

Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials
por: Verma, Subodh, et al.
Publicado: (2015)

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2020)

The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial
por: Hibino, Makoto, et al.
Publicado: (2022)

Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
por: Sherman, Stephen E., et al.
Publicado: (2018)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
por: Byrne, Nikole J., et al.
Publicado: (2017)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Subclinical Valve Thrombosis in Sutureless Bioprosthetic Valves
por: Yanagawa, Bobby, et al.
Publicado: (2017)

Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
por: Luu, Albert Z., et al.
Publicado: (2018)

Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes
por: Terenzi, Daniella C., et al.
Publicado: (2018)

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction
por: Connelly, Kim A., et al.
Publicado: (2019)

Left-Sided Patent Ductus Arteriosus in a Right-Sided Aortic Arch
por: Ng, Ming-Yen, et al.
Publicado: (2014)

Transcatheter Aortic Valve Implantation for Severe Pure Aortic Regurgitation With Dedicated Devices
por: Costanzo, Pierluigi, et al.
Publicado: (2022)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery
por: Hess, David A., et al.
Publicado: (2020)

Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 randomised trial
por: Garg, Vinay, et al.
Publicado: (2017)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Subtle structural abnormalities in genotype positive phenotype ‘negative’ patients with pre-clinical hypertrophic cardiomyopathy (HCM): a blinded, controlled cardiovascular magnetic resonance (CMR) study
por: Deva, Djeven, et al.
Publicado: (2012)

Optimal assessment of right ventricular function using cardiac magnetic resonance cine imaging after Mustard palliation for transposition of the great arteries
por: Jimenez-Juan, Laura, et al.
Publicado: (2011)

Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials
por: Verma, Subodh, et al.
Publicado: (2015)

Investigation of TGFβ1-Induced Long Noncoding RNAs in Endothelial Cells
por: Singh, Krishna K., et al.
Publicado: (2016)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Anti-inflammatory potential of Empagliflozin
por: Pirklbauer, Markus
Publicado: (2021)

Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022)

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
por: Connelly, Kim A., et al.
Publicado: (2020)

Left ventricular structure and diastolic function by cardiac magnetic resonance imaging in hypertrophic cardiomyopathy
por: Chacko, Binita Riya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m7svj3lcdvhs0eqi1mdmqs9jdj